299 related articles for article (PubMed ID: 1512327)
21. Ridogrel as an adjunct to thrombolysis in acute myocardial infarction.
van der Wieken LR; Simoons ML; Laarman GJ; Van den Brand M; Nijssen KM; Dellborg M; Hermens W; Vrolik W
Int J Cardiol; 1995 Nov; 52(2):125-34. PubMed ID: 8749872
[TBL] [Abstract][Full Text] [Related]
22. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study.
Verheugt FW; Liem A; Zijlstra F; Marsh RC; Veen G; Bronzwaer JG
J Am Coll Cardiol; 1998 Feb; 31(2):289-93. PubMed ID: 9462569
[TBL] [Abstract][Full Text] [Related]
23. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
Wallentin L; Bergstrand L; Dellborg M; Fellenius C; Granger CB; Lindahl B; Lins LE; Nilsson T; Pehrsson K; Siegbahn A; Swahn E
Eur Heart J; 2003 May; 24(10):897-908. PubMed ID: 12714021
[TBL] [Abstract][Full Text] [Related]
24. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
[TBL] [Abstract][Full Text] [Related]
25. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
[TBL] [Abstract][Full Text] [Related]
26. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase.
Galvani M; Abendschein DR; Ferrini D; Ottani F; Rusticali F; Eisenberg PR
J Am Coll Cardiol; 1994 Nov; 24(6):1445-52. PubMed ID: 7930274
[TBL] [Abstract][Full Text] [Related]
27. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
[TBL] [Abstract][Full Text] [Related]
28. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
[TBL] [Abstract][Full Text] [Related]
29. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL
Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934
[TBL] [Abstract][Full Text] [Related]
30. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
Jun L; Arnout J; Vanhove P; Dol F; Lormeau JC; Herbert JM; Collen D; Van de Werf F
Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040
[TBL] [Abstract][Full Text] [Related]
31. Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction.
Tranchesi B; Chamone DF; Cobbaert C; Van de Werf F; Vanhove P; Verstraete M
Am J Cardiol; 1991 Jul; 68(2):161-5. PubMed ID: 1829574
[TBL] [Abstract][Full Text] [Related]
32. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
Hsia J; Hamilton WP; Kleiman N; Roberts R; Chaitman BR; Ross AM
N Engl J Med; 1990 Nov; 323(21):1433-7. PubMed ID: 2122251
[TBL] [Abstract][Full Text] [Related]
33. A randomized dose-ranging study of rt-PA in acute myocardial infarction. Effects on coronary patency and fibrinolytic parameters.
Koster RW; van Stralen R; McNeill AJ; Adgey AA; Fox KA; Dymond D; Sponzilli C; Jewitt D; Bucknall C; Kluft C
Eur Heart J; 1990 Aug; 11(8):730-9. PubMed ID: 2118853
[TBL] [Abstract][Full Text] [Related]
34. Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion.
Rebello SS; Huang J; Saito K; Saucedo JF; Bates ER; Lucchesi BR
Eur J Pharmacol; 1999 Jun; 374(3):399-410. PubMed ID: 10422784
[TBL] [Abstract][Full Text] [Related]
35. ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
Malcolm AD; Keltai M; Walsh MJ
Eur Heart J; 1996 Oct; 17(10):1522-31. PubMed ID: 8909909
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of double bolus alteplase in the treatment of acute myocardial infarction.
Purvis JA; Trouton TG; Roberts MJ; McKeown P; Mulholland MG; Dalzell GW; Wilson CM; Patterson GC; Webb SW; Khan MM
Am J Cardiol; 1991 Dec; 68(17):1570-4. PubMed ID: 1746456
[TBL] [Abstract][Full Text] [Related]
37. Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group.
Simoons ML; Arnout J; van den Brand M; Nÿssen K; Verstraete M
Am J Cardiol; 1993 Mar; 71(7):524-8. PubMed ID: 8438737
[TBL] [Abstract][Full Text] [Related]
38. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy.
Van de Werf F; Janssens L; Brzostek T; Mortelmans L; Wackers FJ; Willems GM; Heidbüchel H; Lesaffre E; Scheys I; Collen D
J Am Coll Cardiol; 1993 Aug; 22(2):407-16. PubMed ID: 8335810
[TBL] [Abstract][Full Text] [Related]
39. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial.
Greenbaum AB; Ohman EM; Gibson CM; Borzak S; Stebbins AL; Lu M; Le May MR; Stankowski JE; Emanuelsson H; Weaver WD
Am Heart J; 2007 Oct; 154(4):702-9. PubMed ID: 17892995
[TBL] [Abstract][Full Text] [Related]
40. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.
Théroux P; Pérez-Villa F; Waters D; Lespérance J; Shabani F; Bonan R
Circulation; 1995 Apr; 91(8):2132-9. PubMed ID: 7697841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
